NewsBenzingaReported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Benzinga 2026.10.22 06:49 (GMT+0) Open on Benzinga Other news B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244 Voltus, Google Expand Agreement To Construct 1 GW Virtual Power Plant In PJM Grid B of A Securities Maintains Buy on Meta Platforms, Raises Price Target to $845 Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026 B of A Securities Maintains Buy on SpaceX, Raises Price Target to $275 Bread Financial Holdings Sees FY2026 Sales $4.037B vs $4.024B Est
Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026
